Form 4: Abeona Therapeutics Director Mark Alvino Acquires Shares Through Vesting

Director Mark Alvino of Abeona Therapeutics acquired 36,101 shares of common stock through vesting of restricted stock.

Summary

• Mark Alvino, a director at Abeona Therapeutics, acquired 36,101 shares of common stock on January 31, 2025.
• The shares were acquired through the vesting of restricted stock.
• The vesting occurred at a price of $0.00 per share.
• Following the transaction, Alvino directly owns 100,435 shares of Abeona Therapeutics common stock.
• A portion of the restricted stock may be surrendered to cover tax obligations upon vesting.
• All of the restricted stock will vest on January 31, 2026.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation. It is a positive sign that the director is increasing their stake in the company, but it is not a major event.

Positives

• The vesting of restricted stock indicates a long-term commitment by the director.
• The increase in direct ownership aligns the director's interests with those of shareholders.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who acquire or dispose of company stock. It provides transparency into the ownership changes of key personnel.

Comparison to Industry Standards

• This type of transaction is typical for executives and directors who receive stock-based compensation.
• The vesting schedule is a common practice to incentivize long-term performance and retention.
• Similar filings are made by insiders at other publicly traded companies when they receive or sell shares.

Stakeholder Impact

• The transaction increases the director's alignment with shareholder interests.
• The vesting of shares is a standard part of executive compensation and is not expected to have a significant impact on other stakeholders.

Key Dates

Keywords

Abeona Therapeutics, Mark Alvino, stock acquisition, restricted stock, vesting, director ownership, insider trading